Suboptimal Responders to Adefovir Switching to Entecavir
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing
with Adefovir in patients with a suboptimal response to Adefovir